CA3169026A1 — Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Assigned to GW Research Ltd · Expires 2021-09-02 · 5y expired
What this patent protects
The present invention relates to the use of a cannabidiol (CBD) preparation for use in the treatment of seizures associated with tuberous sclerosis complex (TSC). In particular the invention comprises administering everolimus in combination with a reduced dose of cannabidiol (CBD…
USPTO Abstract
The present invention relates to the use of a cannabidiol (CBD) preparation for use in the treatment of seizures associated with tuberous sclerosis complex (TSC). In particular the invention comprises administering everolimus in combination with a reduced dose of cannabidiol (CBD). In an alternative embodiment the invention relates to the treatment of seizures associated with tuberous sclerosis complex in an everolimus-naive patient which is currently treated with CBD. Preferably the dose of everolimus is reduced by at least 10%.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.